e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Combination therapy in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Asthma control using a combination of mometasone furoate/formoterol: Grouped analysis of three clinical trials
M. White, H. Nolte, E. Meltzer, R. Nathan (Wheaton, Kenilworth, San Diego, Colorado Springs, United States Of America)
Source:
Annual Congress 2010 - Combination therapy in asthma and COPD
Session:
Combination therapy in asthma and COPD
Session type:
Thematic Poster Session
Number:
1209
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. White, H. Nolte, E. Meltzer, R. Nathan (Wheaton, Kenilworth, San Diego, Colorado Springs, United States Of America). Asthma control using a combination of mometasone furoate/formoterol: Grouped analysis of three clinical trials. Eur Respir J 2010; 36: Suppl. 54, 1209
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function
Source: Eur Respir J 2012; 39: 279-289
Year: 2012
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
The effects of mometasone furoate/formoterol treatment on quality of life: An analysis of multi-trial AQLQ findings
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Asthma control using fluticasone propionate/salmeterol: GOAL study re-analysis using GINA 2016 guidelines
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
Source: International Congress 2018 – COPD management
Year: 2018
Efficacy of indacaterol/glycopyrronium
versus
salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
Source: ERJ Open Res, 7 (1) 00816-2020; 10.1183/23120541.00816-2020
Year: 2021
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept